ArticleBritish journal of pharmacology2019
Kazinol U inhibits melanogenesis through the inhibition of tyrosinase-related proteins via AMP kinase activation.
Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Assessment of the Antioxidant and Photoprotective Properties ofInternational journal of molecular sciences · 2024Article
- Phenolic acids inJournal of ginseng research · 2023Article
- The GenusMolecules (Basel, Switzerland) · 2022Review
- Identification of a Novel Class of Anti-Melanogenic Compounds, (Antioxidants (Basel, Switzerland) · 2022Article
- Insights on the Inhibitory Power of Flavonoids on Tyrosinase Activity: A Survey from 2016 to 2021.Molecules (Basel, Switzerland) · 2021Review
- Anti-Melanogenic Properties of Velutin and Its Analogs.Molecules (Basel, Switzerland) · 2021Article
- Article
- Development of a Multi-Target Strategy for the Treatment of Vitiligo via Machine Learning and Network Analysis Methods.Frontiers in pharmacology · 2021Article
- Characterization of Caffeoylquinic Acids fromACS omega · 2020Article
- Jeju Magma-Seawater Inhibits α-MSH-Induced Melanogenesis via CaMKKβ-AMPK Signaling Pathways in B16F10 Melanoma Cells.Marine drugs · 2020Article
- Melanogenic Inhibition and Toxicity Assessment of Flavokawain A and B on B16/F10 Melanoma Cells and Zebrafish (Molecules (Basel, Switzerland) · 2020Article
- Inherited variations in human pigmentation-related genes modulate cutaneous melanoma risk and clinicopathological features in Brazilian population.Scientific reports · 2020Article
- Broussoflavonol B fromMolecules (Basel, Switzerland) · 2020Article
- A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research.British journal of pharmacology · 2020Article
- Pigmentation Effect of Rice Bran Extract in Hair Follicle-Like Tissue and Organ Culture Models.Tissue engineering and regenerative medicine · 2020Article
- Kazinol U inhibits melanogenesis through the inhibition of tyrosinase-related proteins via AMP kinase activation.British journal of pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeKazinol U is a prenylated flavan isolated from an extract of Broussonetia kazinoki Sieb (Moraceae). Kazinol U has shown cytoprotective effects against cytokine-induced apoptotic cell death and induces AMP kinase (AMPK) activation through LKB1 activation. However, kazinol U has not been tested as a regulator of melanogenesis, although bark extract of B. kazinoki has been used as a cosmetic ingredient for skin conditioning. EXPERIMENTAL APPROACH: We cultured mouse, human melanoma cells and normal human melanocytes to demonstrate anti-melanogenic effects of kazinol U. A tyrosinase activity assay, Western blot, RT-qPCR and a luciferase reporter gene assay were performed to determine the anti-melanogenic mechanisms of kazinol U. We confirmed its effect on melanogenesis in vivo using zebrafish. KEY
resultsKazinol U inhibited the expression and activity of tyrosinase, the rate-limiting enzyme in melanogenesis, and reduced tyrosinase expression and activity in response to cAMP-inducing agents. Kazinol U reduced the expression of other melanogenic enzymes, such as tyrosinase-related protein (Tyrp) 1 and Tyrp2, and down-regulated microphthalmia-associated transcription factor (MITF), the master regulator of the tyrosinase gene family. Moreover, kazinol U induced phosphorylation of AMPK and MAPK proteins, which are MITF inhibitors. It also exhibited anti-melanogenic effects in zebrafish, a recently developed in vivo model. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that kazinol U reduces melanogenesis via its inhibitory effect on MITF and its downstream target genes, tyrosinase, Tyrp1 and Tyrp2. This work may provide a basis for the application of kazinol U for the treatment of hyperpigmentation skin disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.